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Introduction: This study’s objectives were to determine whether 
tumor response measured by computed tomography (CT) and evalu-
ated using Response Evaluation Criteria in Solid Tumors (RECIST) 
correlated with overall survival (OS) in patients with non–small-cell 
lung cancer (NSCLC) after neoadjuvant chemotherapy and surgical 
resection.
Methods: We measured primary tumor size on CT before and after 
neoadjuvant chemotherapy in 160 NSCLC patients who underwent 
surgical resection. The relationship between CT-measured response 
(RECIST) and histopathologic response (≤ 10% viable tumor) and 
OS were assessed by Kaplan-Meier survival, univariable, and multi-
variable Cox proportional hazards regression.
Results: There was a statistically significant association between 
CT-measured response (RECIST) and OS (p = 0.03). However, his-
topathologic response was a stronger predictor of OS (p = 0.002), 
with a more pronounced separation of the survival curves when com-
pared with CT-measured response. In multivariable Cox regression 
analysis, only pathologic stage and histopathologic response were 
significant predictors of OS. A 41% overall discordance rate was 
noted between CT RECIST response and histopathologic response. 
CT RECIST classified as nonresponders a subset of patients with his-
topathologic response (8 out of 30 points, 27%) who demonstrated 
prolonged survival after neoadjuvant chemotherapy.
Conclusion: We were unable to show that CT RECIST is a reliable 
predictor of OS in patients with NSCLC undergoing surgical resec-
tion after neoadjuvant chemotherapy. The failure of CT RECIST 
to predict long-term outcome may be because of the inability of 
CT imaging to consistently identify patients with histopathologic 
response. CT RECIST may have only a limited role as an efficacy 
endpoint after neoadjuvant chemotherapy in patients with resectable 
NSCLC.
Key Words: Lung cancer, Neoadjuvant chemotherapy, CT response, 
Histopathologic response, RECIST.
(J Thorac Oncol. 2013;8: 222–228)
Neoadjuvant chemotherapy has been evaluated in patients with nonmetastatic non–small-cell lung cancer 
(NSCLC) in several randomized, phase III trials.1–4 Although 
controversial because of the small size of these trials, the 
impact of neoadjuvant chemotherapy on patient survival 
has generally been favorable. Recently, we described that 
histopathologic response to neoadjuvant chemotherapy was 
strongly associated with long-term overall survival (OS) 
in patients with clinical stage IB to IIIA NSCLC5; patients 
who exhibited less than 10% viable tumor cells after 
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neoadjuvant chemotherapy had a significant reduction in the 
risk of recurrence and/or death compared with patients with 
greater than 10% viable tumor cells in the surgical specimen, 
indicating that this could serve as an intermediary endpoint 
in future neoadjuvant clinical trials. The importance of 
histopathologic response after neoadjuvant chemotherapy 
was also corroborated recently by a review of two phase III 
neoadjuvant chemotherapy intergroup studies from France.6 
However, the utility of standard computed tomography (CT) 
Response Evaluation Criteria in Solid Tumors (RECIST) after 
neoadjuvant chemotherapy has not been well studied to date 
in patients with resectable NSCLC. We therefore investigated 
whether tumor response measured by CT using the RECIST7 
predicted OS and histopathologic response in patients 
with locally advanced NSCLC who received neoadjuvant 
chemotherapy and surgical resection.
PATIENTS AND METHODS
Patients and Treatment
We retrospectively reviewed the medical records of 
patients with NSCLC treated at the University of Texas M. 
D. Anderson Cancer Center from January 2001 to December 
2008 who underwent neoadjuvant chemotherapy. During 
this period, 160 patients had CT imaging before and after 
completion of neoadjuvant therapy and underwent surgical 
resection with histopathologic assessment of tumor response 
(Table 1). From the patient medical records, we obtained 
detailed clinical and pathological information for all patients 
in the study group, including demographic data, pathologi-
cal and clinical tumor-node-metastasis staging, and OS. This 
study was approved by the University of Texas M. D. Anderson 
Institutional Review Board and was performed in compliance 
with the Health Insurance Portability and Accountability Act.
CT and Measurements
The CTs used in this study were performed before and 
after neoadjuvant chemotherapy. All chest CTs were performed 
on a General Electric CT scanner (LiteSpeed, LightSpeed, or 
HiSpeed; GE Medical Systems, Milwaukee, WI). The CT scan 
was obtained within 2 weeks before starting chemotherapy 
and within 4 weeks of completion of chemotherapy. In the 
RECIST assessment method,7 lesion size was based on the 
longest dimension (LD) of the primary tumor. Measurements 
were performed by a single board-certified thoracic radiologist 
(JJE) who was blinded to long-term outcome to reduce interob-
server variability and bias.8 The percentage change in the size 
of the target lesion was calculated between the pre-chemother-
apy and post-chemotherapy measurements. Patients with dis-
appearance of the lesion were defined as achieving complete 
response (CR); a greater than 30% decrease in the LD of the 
target lesion were defined as achieving partial response (PR); 
a greater than 20% increase in LD or the appearance of new 
lesions was defined as having progressive disease (PD).7 All 
other outcomes were defined as stable disease (SD). Patients 
who achieved a CR or PR by RECIST were defined as radio-
logic responders while patient who demonstrated SD or PD 
were defined as radiologic nonresponders.
Histopathologic Response
Histopathologic response was assessed as previously 
described by Pataer et al.5 Hematoxylin and eosin (H&E)-
stained slides were assessed of sections of the gross residual 
tumor resected after neoadjuvant chemotherapy (at least 1 
section per cm of tumor greatest diameter). The percentage 
of residual tumor was quantified by comparing the estimated 
cross-sectional area of the viable tumor foci to estimated 
cross-sectional areas of necrosis, fibrosis, and inflammation 
on each slide. The results for all slides were averaged together 
to determine the mean values of percentage of viable tumor 
cells for each patient. We previously demonstrated that a 
cut-off of 10% viable tumor cells could distinguish patients 
with a high versus low probability of long-term disease-free 
and OS.5 As such, patients were considered to be pathologic 
responders if they had less than 10% viable tumor cells and 
pathologic nonresponders if they had greater than 10% viable 
tumor cells.9–11
TABLE 1.  Patient Demographics and Treatment 
Characteristics 
Age median (range, yrs) 63 (40–85)
 Sex: n (%)
 Men 92 (57%)
 Women 68 (43%)
Histology: n (%)
 Adenocarcinoma 68 (43%)
 Squamous cell carcinoma 51 (32%)
 Othersa 41 (25%)
Tumor size (cm): n (%)
 0.0–2.0 40 (25%)
 2.1–3.0 40 (25%)
 3.1–5.0 47 (29%)
 >5.0 33 (21%)
Clinical stage: n (%)
 IA/B 52 (32%)
 IIA/B 35 (22%)
 IIIA/B 64 (40%)
 IV 9 (6%)
Type of resection n (%)
 Wedge or segmentectomy 4 (3%)
 Bilobectomy or lobectomy 143 (89%)
 Pneumonectomy 13 (8%)
Neoadjuvant chemotherapy: n (%)
 T+C 143 (89%)
 Carboplatin 107 (67%)
 Cisplatin 53 (33%)
 Taxol 76 (48%)
 Taxotere 68 (42%)
 Gemcitabine 13 (8%)
 Etoposide 3 (2%)
 Treatment cycle median (range, cycles) 3 (1–11)
aOthers (32 patients with NSCLC-NOS, 4 with adenosquamous carcinoma, 3 with 
neuroendocrine tumor, 1 with large cell and 1 with sarcoma). AJCC/UICC 6th edition. 
T, taxol or taxotere; C, caboplatin or cisplatin. 
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Statistical Analysis
Correlations were evaluated using Pearson’s linear test 
or the Spearman rank test. OS was calculated from the time 
of surgery to the time of death from any cause or to the time 
of the patient’s last follow-up visit, after which the data were 
censored. Survival probability as a function of time was com-
puted by the Kaplan-Meier method. The log-rank test was used 
to compare OS between groups. Univariable Cox proportional 
hazards regression analysis was used to examine the asso-
ciation between various prognostic factors and OS. Variables 
found to be significant in univariable analysis (p < 0.25) were 
then evaluated by multivariable analysis using the Cox propor-
tional hazards regression model with backward stepwise Wald 
elimination. In multivariable analysis, p less than 0.05 was 
taken to be significant. Statistical analyses were performed 
using SPSS version 19.0 software (SPSS, Inc., Chicago, IL).
RESULTS
Patient Demographics and 
Treatment Characteristics
The study population included 92 men (57%) and 68 
women (43%) with a median age of 64 years (range, 40–85 
years). Histologic tumor types are shown in Table 1. All patients 
were treated with a platinum-based doublet, and the majority 
received a taxane and platinum (143 patients, 89%). The median 
number of treatment cycles was 3 (range, 1–11 cycles) and 143 
patients (89%) received a lobectomy or bilobectomy (Table 1).
Response to Neoadjuvant Chemotherapy 
by Radiologic and Pathologic Criteria
CT RECIST demonstrated two (1%) patients with 
a complete response and 78 (49%) patients with a partial 
response. Stable disease occurred in 75 (47%) patients and 
disease progression was rare and seen in only 5 (3%) patients 
after neoadjuvant chemotherapy. Histopathologic response 
(≤ 10% viable tumor) was seen in 30 of 160 patients (19%) 
and occurred more frequently in patients with CR/PR by CT 
criteria, compared with patients with SD/PD (27% versus 
10%, p < 0.005) (Supplementary Table 1, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A385). There 
was, however, a 41% discordance rate between histopathologic 
response and CT RECIST response (8 of 80 patients had a 
histopathologic response despite being classified as SD/
PD by CT criteria, and 58 of 80 patients did not achieve 
pathologic response despite being classified as CR/PR by CT 
criteria) (Fig. 1). The sensitivity of CT RECIST to identify 
histopathologic responders was 73% and the specificity was 
55%. Representative examples of the dissociation between 
response by CT and pathologic criteria are shown in Fig. 2.
Relationship Between CT and 
Histopathologic Response and OS
We analyzed the relation between response assessed 
with CT radiologic criteria (RECIST), histopathologic cri-
teria, and OS in NSCLC patients who received neoadjuvant 
chemotherapy. The Kaplan-Meier survival curves in Fig. 3A 
show that patients with CR or PR by radiologic criteria have 
improved OS compared with patients with SD or PD (p = 
0.03). Patients with a histopathologic response have a statisti-
cally significant improvement in OS compared with patients 
that did not achieve a histopathologic response (p = 0.002) 
(Fig. 3B). The separation of the curves in Fig. 3B is more pro-
nounced when compared with Fig. 3A, suggesting that his-
topathologic response may more accurately identify patients 
with a higher chance of long-term survival compared with 
RECIST.
On univariable analysis, CT response, histopathologic 
response, and pathologic stage were significantly associated 
with OS (Table 2). These variables were then included on the 
multivariable analysis. Wald stepwise elimination excluded CT 
response from the multivariable model, indicating a stronger 
association of OS with histopathologic response compared 
with CT response. Multivariable Cox proportional hazards 
FIGURE 1.  Distribution of the percentage change in 
CT-measured size of the primary tumor between pre-chemo-
therapy and post-chemotherapy measurements in 160 non–
small-cell lung cancer patients who received neoadjuvant 
chemotherapy. CT, computed tomography.
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regression analysis revealed an association of both pathologic 
stage (p < 0.001) and histopathologic response (p = 0.05) 
with OS (Table 2). We repeated the multivariable analysis 
using the Cox proportional hazards regression model with 
backward stepwise Wald elimination, applying more stringent 
criteria for CT response (i.e., at least 50% or 70% reduction in 
tumor size). In both cases, CT response was not significantly 
associated with overall survival (p = 0.23 for CT response 
at the 50% threshold, and p = 0.98 for CT response at the 
70% threshold). As observed for the 30% threshold, in both 
cases (50% and 70%), backward stepwise Wald elimination 
excluded CT response from the multivariable model, while 
maintaining percentage of viable tumor cells and pathological 
stage. We conclude, from these findings, that even when using 
more stringent thresholds to define CT response, pathologic 
response still outperforms CT response in predicting overall 
survival.
Complementary Prognostic Value of 
Radiological and Histopathologic Criteria
To determine whether the failure of CT RECIST 
response criteria to predict OS was because of lack of 
correlation with histopathologic response we combined 
radiologic CT RECIST and histopathologic criteria into four 
subgroups: (1) patients who were CT responders and histo-
pathologic responders, (2) patients who were CT responders 
but histopathologic nonresponders, (3) patients who were 
CT nonresponders but histopathologic responders, and (4) 
patients who were CT nonresponders and histopathologic 
nonresponders. As shown in Fig. 4, Kaplan-Meier survival 
analysis indicated that the four subgroups had significantly 
different OS (p = 0.006). Patients who were CT respond-
ers and histopathologic responders had prolonged OS but 
CT nonresponders with histopathologic responders also had 
prolonged survival even greater than CT responders and his-
topathologic nonresponders. These results suggest that his-
topathologic response may be the most important predictor 
of long-term survival and that CT response may not be pre-
dictive in all patients because CT response does not identify 
all patients who have a pathologic response. Furthermore, in 
patients who were pathologic nonresponders, there was no 
significant difference in survival between CT responders and 
CT nonresponder (p = 0.14, data not shown), suggesting that 
CT response does not compensate for a lack of histopatho-
logic response after neoadjuvant chemotherapy with regards 
to improvement in OS.
Pre-chemotherapy Post-chemotherapy CT  Response
2.3 cm 2.2 cm
CT RECIST
(-4%, SD)
Path
(5% Viable tumor)
A B
6.0 cm 3.8 cm
C D
CT RECIST
(-37%, PR)
Path
(86% Viable tumor)
FIGURE 2.  CTs of lung tumors, 
showing examples of dissociation 
between radiological assessment of 
tumors and pathologic response. (A, 
B) No CT response to treatment by 
RECIST, despite 5% of viable tumor 
cells remaining after neoadjuvant 
therapy. (C, D) PR to treatment by 
CT criteria, but 86% of viable tumor 
cells remained in the resected speci-
men. The percentages shown are 
the change in the size of the target 
lesion between pre-chemotherapy 
and post-chemotherapy measure-
ments. CT, computed tomography; 
CR, complete response; PR, partial 
response; PD, progressive disease; 
SD, stable disease; RECIST, Response 
Evaluation Criteria in Solid Tumors.
Su
rv
iv
al
 P
ro
ba
bi
lit
y
CR/PR (N=80)
SD/PD (N=80)
P = 0.03
% Viable tumorCT RECIST Criteria
Su
rv
iv
al
 P
ro
ba
bi
lit
y 10% (N=30)
>10% (N=130)
P = 0.002
BA
Time (months) Time (months)
FIGURE 3.  Kaplan-Meier estimates of OS for CT (RECIST) and 
histopathologic response criteria. (A) CT-RECIST grouping into 
responders and nonresponders demonstrates a difference in 
OS (p = 0.03) (B) With histopathologic response, OS was sig-
nificantly different between responders (≤ 10% viable tumor) 
and nonresponders (> 10% viable tumor, p = 0.002), with a 
more pronounced separation of the curves when compared 
to CT-RECIST. CT, computed tomography; RECIST, Response 
Evaluation Criteria in Solid Tumors; OS, overall survival. 
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DISCUSSION
The current standard of care in North America and 
Europe after surgical resection of lymph node-positive NSCLC 
patients is cisplatin-based adjuvant chemotherapy. These rec-
ommendations are based on data from three randomized con-
trolled studies12–14 and a meta-analysis from five trials with 
4584 patients.15 Additionally, neoadjuvant chemotherapy is 
also being used in patients with nonmetastatic NSCLC1–4 and 
a recent meta-analysis from 13 randomized neoadjuvant trials 
(3206 patients), demonstrated a HR for death of 0.84 (95% 
confidence interval [CI] 0.77–0.92, p = 0.0001) in favor of 
neoadjuvant treatment, translating into an absolute improve-
ment of OS at 5 years of 6%.16 These studies also demon-
strated that neoadjuvant treatment has activity in NSCLC and 
(1) elicits objective responses (assessed by imaging studies) 
in at least 40% of the patients, (2) has no significant increase 
in peri-operative mortality,17 and (3) does not appear to nega-
tively impact disease resectability.
A potential advantage of developing neoadjuvant 
treatment strategies for resectable NSCLC is the opportunity 
to evaluate response as an intermediary endpoint of efficacy. 
If a close correlation between response to treatment and OS is 
demonstrated, then it would be possible to design more efficient 
clinical trials incorporating novel neoadjuvant therapies that 
would evaluate response as a surrogate marker for improved 
long-term outcomes. This strategy would allow for an early 
readout of efficacy, and could streamline drug development. 
It would also allow investigation of intensification of adjuvant 
treatment in patients who did not respond adequately to 
neoadjuvant therapy, in an attempt to improve long-term 
outcomes.
In this study, we demonstrate that in 160 patients 
with resectable NSCLC who received neoadjuvant chemo-
therapy, there was an association between CT-measured 
tumor response (RECIST) and OS (p = 0.03). However, his-
topathologic response was a stronger predictor of OS (p = 
TABLE 2.  Univariable and Multivariable Cox Proportional 
Hazard Analyses for Overall 
Characteristics No. of Patients HR 95% CI P value
Univariable Cox 
regression model
 CT Response 
   Responder (CR/PR) 80 1.00
   Nonresponder  
(SD/PD)
80 1.68 1.04–2.7 0.03
 Viable tumor
  ≤10% 30 1.00
  >10% 130 3.56 1.52–8.32 0.003
 Pathological stages <0.001
  0/IA/IB 67 1.00
  IIA/IIB 43 2.08 1.07–4.07 0.03
  IIIA/IIIB 41 4.40 2.41–8.03 <0.001
  IV 9 5.46 2.13–13.98 <0.001
 Histology
   Adenocarcinoma 
(reference)
68 1.00
  Squamous cell 
carcinoma
51 0.67 0.38–1.19 0.18
  Others 41 0.92 0.52–1.61 0.76
  Age (continuous) 160 1.01 0.98–1.04 0.42
 Sex 
  Women (reference) 68 1.00
   Men 92 0.88 0.55–1.41 0.59
Multivariable Cox  
regression model
 Viable tumor
  ≤10% 30 1.00
  >10% 130 2.39 0.99–5.78 0.05
 Pathological stages <0.001
  0/IA/IB 67 1.00
  IIA/IIB 43 1.70 0.86–3.36 0.13
  IIIA/IIIB 41 3.54 1.91–6.58 <0.001
  IV 9 4.71 1.83–12.11 <0.001
AJCC/UICC 6th edition.
CT, computed tomography; CI, confidence interval; HR, hazard ratio; CR, complete 
response; PR, partial response; PD, progressive disease; SD, stable disease.
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CT responder/
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Time (months)
CT/Path
No. of 
Patients
Median Survival  
(months)
5 Years 
Survival P Value
CT Responder/
Path Responder 22 NR 85% Ref
CT Non-responder/
Path Responder 8 NR 75% NS
CT Responder/
Path Non-responder 58 63 58% 0.01
CT Non-responder/
Path Non-responder 72 47 35% 0.002
P = 0.006 
FIGURE 4.  Kaplan-Meier estimates of overall survival for 
response assessment based on both CT Response Evaluation 
Criteria in Solid Tumors and histopathologic criteria: survival 
correlates with histopathologic response even when com-
bined with CT Response Evaluation Criteria in Solid Tumors 
criteria (5 yr survival—histopathologic response 85% and 
75% for CT responders and nonresponders, respectively, 
versus nonhistopathologic response 53% and 38%, for CT 
responders and nonresponders, respectively, p < 0.001). 
CT, computed tomography.
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0.002), with a more pronounced separation of the survival 
curves when compared with CT-measured response (Fig. 3). 
The lower performance of CT-measured tumor response ( 
RECIST) in predicting OS after neoadjuvant chemotherapy 
may be owing in part to the inability of standard measure-
ments of CT tumor size changes to predict histopathologic 
response. As demonstrated in Fig. 4, 58 of 80 patients with a 
CT response failed to have a histopathologic response while 
eight of 30 patients with a histopathologic response failed to 
demonstrate a response on CT RECIST response. Sensitivity 
was 73% but specificity was only 55%. This inability of CT 
RECIST-measured tumor size changes to predict histopatho-
logic response may be because of various factors including 
the fact that NSCLC tumors are pathologically heteroge-
neous in composition and include cancer cells, stromal tis-
sue, and associated inflammatory cells.18,19 Because of this, 
CT RECIST response assessment may provide only a macro-
scopic evaluation of the primary tumor, and it is possible that 
the CT RECIST-measured tumor size changes are confounded 
by inflammatory or fibrotic changes. This latter possibility 
has been reported previously in patients with advanced stage 
NSCLC.18
These observations have significant implications for 
ongoing clinical trials that utilize CT imaging response criteria 
(RECIST) as intermediary endpoints of treatment response 
in both metastatic and nonmetastatic NSCLC20 as well as 
other tumor types.19 Several studies have suggested that there 
may be more accurate CT response criteria than RECIST21,22 
such as volumetric response measurements with automatic 
deformable image registration (ADIR). Similarly in other 
tumor types, Choi and colleagues demonstrated that GIST 
tumors treated with imatinib were more accurately assessed 
with small CT changes in tumor size or density rather than 
standard RECIST criteria, while Chun and colleagues found 
that colorectal liver metastases were more accurately assessed 
with morphologic CT criteria than RECIST.23 Other authors 
have suggested that monitoring response with apoptosis 
molecular imaging or contrast-enhanced MRI may be more 
accurate.24–26
It has also been suggested that response assessed by 
[18F] fluorodeoxyglucose (FDG) positron emission tomog-
raphy (PET) after chemotherapy may be more accurate than 
CT-measured responses (RECIST) in patients with NSCLC.27–
31 Not all authors are in agreement with this finding, however, 
as demonstrated by Tanvetyanon et al who evaluated two con-
secutive phase II neoadjuvant chemotherapy trials and found 
that CT response (RECIST) was more accurate than PET.32 
This is not unreasonable since FDG-PET imaging may be 
affected by the cellular composition of the primary tumor as 
well as the therapeutic-induced inflammatory response.33 In 
this regard, the exact mechanism of FDG uptake and distribu-
tion among cells within the primary tumor is unknown and 
although FDG uptake in lung cancer is thought to be primar-
ily because of the tumor cells, there is a variable contribu-
tion from the inflammatory response owing to competitive 
uptake in macrophages and lymphocytes.33 Animal studies 
have shown that up to 30% of the FDG uptake in a tumor 
may be caused by the macrophage/monocyte system and that 
some tumors retain high FDG uptake at the end of therapy 
even with complete histopathological response at the time of 
resection.34,35 It has recently been reported that the prediction 
of histopathologic response in patients with locally advanced 
NSCLC who received neoadjuvant chemotherapy followed 
by curative surgery is more accurate when defined by a com-
bined radiologic-metabolic response using CT and FDG-PET 
compared to radiologic and metabolic response alone.36,37 
Nevertheless, the accuracy for the prediction of histopatho-
logic response was only 73% to 82% in radiologic-metabolic 
responders (compared with 70% in radiologic responders and 
52% to 75% in metabolic responders).37
In conclusion, our study suggests that changes in 
CT-measured tumor size by standard RECIST are unreliable 
in predicting OS or histopathologic response after neoadjuvant 
therapy in resectable NSCLC. Because of the overall poor 
reliability of CT in predicting therapeutic response and OS, 
CT RECIST may have only a limited role as an endpoint for 
efficacy in clinical trials with novel therapeutics in metastatic 
and nonmetastatic NSCLC. In the future, novel CT, PET, 
or molecular imaging response criteria may need to be 
developed beyond standard CT RECIST changes in tumor 
size to accurately serve as surrogate endpoints for treatment 
efficacy.
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